The information on this website is generated using AI and we cannot guarantee its accuracy. Please use it as reference information only.

CRISPR Therapeutics reports 83% Month 3 response in systemic sclerosis trial

Nov 8, 2026 15:30 (11h ago)

Verifying

CRISPR Therapeutics presented systemic sclerosis results for investigational zugo-cel at ACR Convergence 2026.
83% (5/6) receiving standard lymphodepletion achieved rCRISS-25 responses at Month 3.
All 21 treated patients had no CRS above Grade 2, ICANS, IEC-HS or deaths reported.